ResVax (respiratory syncytial virus F-protein nanoparticle vaccine) / Novavax - LARVOL DELTA

Novavax to Present COVID-19, Influenza and RSV Candidate Vaccine Data at World Vaccine Congress Washington 2020 (GlobeNewswire) - "Novavax, Inc....today announced that it will present on its lead vaccine candidates, NVX-CoV2373, NanoFlu™ and ResVax™, the Company’s COVID-19, influenza and respiratory syncytial virus (RSV) vaccines. The presentations are part of the 2020 World Vaccine Congress Washington, taking place virtually September 28-October1, 2020."

Clinical • Live event • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The long road to protect infants against severe RSV lower respiratory tract illness. (PubMed, F1000Res) - "However, palivizumab and the recent results of the Novavax maternal immunization trial with ResVax demonstrate that severe RSV LRTI can be prevented by mAb and by maternal immunization (at least to a certain extent). In fact, disease prevention may also decrease the rates of recurrent wheezing and all-cause pneumonia for at least 180 days. In this review, we discuss the history of RSV vaccine development, previous and current vaccine strategies undergoing evaluation, and recent information about disease burden and its implications for the effects of successful preventive strategies."

Journal • Review • Asthma • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults (clinicaltrials.gov) - P2; N=300; Recruiting; Sponsor: Novavax

New P2 trial • Biosimilar • Immunology

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization (clinicaltrials.gov) - P3; N=4636; Completed; Sponsor: Novavax; Active, not recruiting ➔ Completed

Clinical • Trial completion

"RSV vaccine's star falls further following FDA setback https://t.co/Ox2StdI4q4 #biotech #drugtrial @NovavaxInc #research @US_FDA #USA #vaccines" (@ThePharmaLetter)

"@FDA_Drug_Info @US_FDA @BillGates Not approved? So badly needed!! Novavax ResVax showed efficacy against the secondary endpoint of RSV LRTI hospitalization. The vaccine also reduced severe RSV hypoxemia, or an abnormally low level of oxygen, by 60 percent in the first months.." (@AL_P26)

Clinical

"$NVAX Novavax Nears Maternal Immunization Results for RSV Vaccine https://t.co/ZdZ0keukxE" (@BioStocks)